Background de novo metastatic breast cancer (dnMBC) is responsible for 6–10% of breast
cancer presentations with increasing incidence and has remained resistant to detection by
mammography screening. Recent publications hypothesized that in addition to poor
screening uptake, the presentation of dnMBC may be due to its unfavourable biology which
remains unknown at the molecular level. Here we investigated the tumour biology of dnMBC
in the form of clinicopathology, genomic alterations and differential gene expression to …